Zura Bio Sees Unusually High Options Volume (NASDAQ:ZURA)

Zura Bio Limited (NASDAQ:ZURA) saw unusually large options trading activity on Wednesday. Traders acquired 2,384 call options on the stock. This represents an increase of 728% compared to the average volume of 288 call options.

Zura Bio Trading Up 3.5%

Shares of Zura Bio stock traded up $0.14 on Wednesday, reaching $4.13. 72,823 shares of the company were exchanged, compared to its average volume of 656,238. The company has a market capitalization of $391.86 million, a price-to-earnings ratio of -3.79 and a beta of 0.09. Zura Bio has a one year low of $0.98 and a one year high of $7.44. The company has a 50-day moving average of $5.58 and a 200 day moving average of $5.22.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Analysts predict that Zura Bio will post -0.73 earnings per share for the current year.

Insider Buying and Selling at Zura Bio

In other news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of Zura Bio stock in a transaction dated Thursday, February 26th. The shares were bought at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the completion of the transaction, the insider directly owned 6,552,725 shares in the company, valued at $40,954,531.25. This trade represents a 43.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 22.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zura Bio

Hedge funds have recently bought and sold shares of the company. Suvretta Capital Management LLC increased its position in Zura Bio by 1.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock worth $29,171,000 after buying an additional 94,110 shares during the last quarter. VR Adviser LLC lifted its position in shares of Zura Bio by 15.4% in the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock valued at $28,008,000 after buying an additional 713,899 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares during the last quarter. Siren L.L.C. boosted its stake in shares of Zura Bio by 187.3% during the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after acquiring an additional 2,434,866 shares during the period. Finally, Commodore Capital LP acquired a new position in shares of Zura Bio during the 1st quarter worth approximately $19,338,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ZURA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. Oppenheimer decreased their price objective on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Friday, March 20th. Wedbush initiated coverage on shares of Zura Bio in a report on Monday, February 9th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Chardan Capital lifted their price target on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zura Bio presently has a consensus rating of “Moderate Buy” and an average target price of $10.75.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.